GGrantIndex
← Leaderboards

Providence Portland Medical Center

Portland, OR

Compare ↔
$41,658,790
Total funding
36
Grants

Funding over time

peak $2.8M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$41,548,747 · 34
CDC$110,043 · 1
AHRQ$0 · 1

By mechanism

R01$25,269,830 · 17
U10$9,850,377 · 1
R21$4,316,174 · 10
K22$877,829 · 2
R00$710,098 · 1
R29$201,262 · 1

Investigators at Providence Portland Medical Center

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

1Michael James Gough$5,824,6863 gr2Bernard A Fox$5,302,4323 gr3Andrew D Weinberg$4,972,0043 gr4Brendan D Curti$3,242,0714 gr5William L Redmond$2,781,5454 gr6Marka Crittenden$2,669,2474 gr7Walter J Urba$2,009,8644 gr8Hong-Ming Hu$1,630,9632 gr

Largest grants

Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$1,205,769
R01 · FY2025 · CA
Columbia River Oncology Program$986,419
U10 · FY2012 · CA
COLUMBIA RIVER ONCOLOGY PROGRAM$785,000
U10 · FY2006 · CA
COLUMBIA RIVER ONCOLOGY PROGRAM$776,500
U10 · FY2007 · CA
COLUMBIA RIVER ONCOLOGY PROGRAM$752,177
U10 · FY2003 · CA
Columbia River Oncology Program$745,543
U10 · FY2009 · CA
COLUMBIA RIVER ONCOLOGY PROGRAM$745,543
U10 · FY2008 · CA
Columbia River Oncology Program$721,977
U10 · FY2011 · CA
Columbia River Oncology Program$705,543
U10 · FY2010 · CA
COLUMBIA RIVER ONCOLOGY PROGRAM$704,456
U10 · FY2001 · CA
COLUMBIA RIVER ONCOLOGY PROGRAM$663,884
U10 · FY2004 · CA
COLUMBIA RIVER ONCOLOGY PROGRAM$645,000
U10 · FY2005 · CA
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$593,078
R01 · FY2021 · CA
WESTERN ONCOLOGY RESEARCH CONSORTIUM$589,569
U10 · FY2013 · CA
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$582,888
R01 · FY2023 · CA
COLUMBIA RIVER ONCOLOGY PROGRAM$578,493
U10 · FY2002 · CA
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$571,136
R01 · FY2024 · CA
COLUMBIA RIVER ONCOLOGY PROGRAM$450,273
U10 · FY2000 · CA
High dose radiation therapy to direct immune responses to pancreatic cancer$391,875
R01 · FY2020 · CA
High dose radiation therapy to direct immune responses to pancreatic cancer$391,875
R01 · FY2019 · CA